In this webinar, BioAgilytix’s Dr. Arno Kromminga summarizes the recommendations from the AAPS Ligand Binding Assay Biosimilar subcommittee and Biosimilars Action Program Committee on the Development and Validation of PK, Anti-Drug Antibody (ADA), and Neutralization Antibody Assays (NAB) for Biosimilar Drug Development, and describes how this information can be used to reduce the risks present in biosimilar drug development.
Services
Platforms